JP2016508987A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016508987A5 JP2016508987A5 JP2015551117A JP2015551117A JP2016508987A5 JP 2016508987 A5 JP2016508987 A5 JP 2016508987A5 JP 2015551117 A JP2015551117 A JP 2015551117A JP 2015551117 A JP2015551117 A JP 2015551117A JP 2016508987 A5 JP2016508987 A5 JP 2016508987A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- cancer
- therapy
- composition
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000014150 Interferons Human genes 0.000 claims 19
- 108010050904 Interferons Proteins 0.000 claims 19
- 229940079322 interferon Drugs 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 210000000988 bone and bone Anatomy 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 238000011319 anticancer therapy Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000012377 drug delivery Methods 0.000 claims 3
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 2
- 238000001815 biotherapy Methods 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000004876 tela submucosa Anatomy 0.000 claims 2
- 206010006002 Bone pain Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 238000010317 ablation therapy Methods 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000004379 membrane Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 238000002663 nebulization Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 229940126703 systemic medication Drugs 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361749570P | 2013-01-07 | 2013-01-07 | |
| US61/749,570 | 2013-01-07 | ||
| US201361779711P | 2013-03-13 | 2013-03-13 | |
| US61/779,711 | 2013-03-13 | ||
| PCT/CN2014/070212 WO2014106492A2 (en) | 2013-01-07 | 2014-01-07 | Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020066723A Division JP2020105223A (ja) | 2013-01-07 | 2020-04-02 | インターフェロンの経皮及び／又は経粘膜投薬による骨ガン、皮膚癌、皮下腫瘍、粘膜癌及び／又は粘膜下腫瘍を治療する方法と組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016508987A JP2016508987A (ja) | 2016-03-24 |
| JP2016508987A5 true JP2016508987A5 (enExample) | 2017-02-09 |
Family
ID=51062515
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551117A Pending JP2016508987A (ja) | 2013-01-07 | 2014-01-07 | インターフェロンの経皮及び／又は経粘膜投薬による骨ガン、皮膚癌、皮下腫瘍、粘膜癌及び／又は粘膜下腫瘍を治療する方法と組成物 |
| JP2015551113A Pending JP2016506413A (ja) | 2013-01-07 | 2014-01-07 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
| JP2019190263A Pending JP2020023547A (ja) | 2013-01-07 | 2019-10-17 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
| JP2020066723A Pending JP2020105223A (ja) | 2013-01-07 | 2020-04-02 | インターフェロンの経皮及び／又は経粘膜投薬による骨ガン、皮膚癌、皮下腫瘍、粘膜癌及び／又は粘膜下腫瘍を治療する方法と組成物 |
| JP2021200049A Pending JP2022031331A (ja) | 2013-01-07 | 2021-12-09 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551113A Pending JP2016506413A (ja) | 2013-01-07 | 2014-01-07 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
| JP2019190263A Pending JP2020023547A (ja) | 2013-01-07 | 2019-10-17 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
| JP2020066723A Pending JP2020105223A (ja) | 2013-01-07 | 2020-04-02 | インターフェロンの経皮及び／又は経粘膜投薬による骨ガン、皮膚癌、皮下腫瘍、粘膜癌及び／又は粘膜下腫瘍を治療する方法と組成物 |
| JP2021200049A Pending JP2022031331A (ja) | 2013-01-07 | 2021-12-09 | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US20150352188A1 (enExample) |
| EP (3) | EP3895725A3 (enExample) |
| JP (5) | JP2016508987A (enExample) |
| KR (4) | KR20210077005A (enExample) |
| CN (2) | CN104902917A (enExample) |
| AU (2) | AU2014204386B2 (enExample) |
| CA (2) | CA2897335A1 (enExample) |
| HK (2) | HK1214528A1 (enExample) |
| TW (3) | TWI718086B (enExample) |
| WO (2) | WO2014106459A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI718086B (zh) | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
| US10877024B2 (en) | 2015-05-12 | 2020-12-29 | Superlab Far East Limited | Methods of determining interferon having direct inhibitory effects on tumors and uses thereof |
| EP3576765B1 (en) | 2017-02-06 | 2025-07-16 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| CN108721603B (zh) * | 2017-04-14 | 2020-11-13 | 中国医学科学院基础医学研究所 | 干扰素α-1a在制备用于治疗癌症的药物中的用途 |
| KR101880015B1 (ko) * | 2017-12-08 | 2018-07-19 | 아주대학교산학협력단 | 인터페론 감마를 유효성분으로 함유하는 신경섬유육종 예방 또는 치료용 조성물 |
| JP7531490B2 (ja) * | 2018-11-27 | 2024-08-09 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | がんを治療するための組成物および方法 |
| US20220251605A1 (en) * | 2019-06-14 | 2022-08-11 | The Brigham And Women's Hospital, Inc. | Membrane attack complexes and uses thereof |
| CN111658779A (zh) * | 2020-06-22 | 2020-09-15 | 四川大学华西医院 | 治疗新型冠状病毒肺炎的联合用药物 |
| EP4282426A4 (en) * | 2021-01-21 | 2024-11-27 | Xiamen Amoytop Biotech Co., Ltd. | Method and pharmaceutical combination for preventing cancer recurrence |
| JP2024504341A (ja) * | 2021-01-21 | 2024-01-31 | シャーメン アモイトップ バイオテック カンパニー， リミテッド | 癌を治療するためのインターフェロンベースの方法及び組合せ医薬 |
| US11759434B2 (en) * | 2022-02-03 | 2023-09-19 | Sytheon Limited | Methods and compositions for treating melanoma and non-melanoma skin cancers |
| CN114533706B (zh) * | 2022-02-15 | 2022-10-14 | 深圳市利云德生物技术有限公司 | 一种用于防治呼吸道疾病的雾化吸入制剂及其应用 |
| WO2024076973A1 (en) * | 2022-10-04 | 2024-04-11 | Brown University | Compositions and methods of delivering large proteins |
| WO2024186193A1 (ko) * | 2023-03-08 | 2024-09-12 | 인제대학교 산학협력단 | 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2005169A (en) * | 1932-08-27 | 1935-06-18 | Rowe Andrew Reed | Casting metal ingots |
| US4672108A (en) | 1981-12-07 | 1987-06-09 | Hoffmann-La Roche Inc. | Crystalline human leukocyte interferon |
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US4681930A (en) | 1983-09-20 | 1987-07-21 | Hoffmann-La Roche Inc. | Immune interferon and a method for its extraction and purification |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
| US4846782A (en) * | 1986-03-14 | 1989-07-11 | Schering Corporation | Treatment of cancer with interferon and radiotherapy |
| US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
| ES2141108T3 (es) | 1991-07-02 | 2000-03-16 | Inhale Inc | Metodo y dispositivo para proporcionar medicamentos en aerosol. |
| RU2054180C1 (ru) | 1991-08-21 | 1996-02-10 | Жирнов Олег Петрович (н/п) | Способ лечения вирусных респираторных инфекций |
| AU4829593A (en) | 1992-09-23 | 1994-04-12 | Fisons Plc | Inhalation device |
| DE69322789T2 (de) | 1992-10-19 | 1999-07-01 | Dura Pharmaceuticals, Inc., San Diego, Calif. | Trockenpulverinhalator |
| AU5883694A (en) | 1993-01-19 | 1994-08-15 | Glaxo Group Limited | Device |
| US5441734A (en) | 1993-02-25 | 1995-08-15 | Schering Corporation | Metal-interferon-alpha crystals |
| DE69431071T2 (de) * | 1993-12-29 | 2003-03-20 | Matrix Pharma | Zusammensetzung für lokale freigabe von zytostatika |
| TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| US5480640A (en) | 1995-05-02 | 1996-01-02 | Schering Corporation | Alpha interferon for treating prostate cancer |
| ATE328069T1 (de) | 1995-10-13 | 2006-06-15 | Harvard College | Phosphopantethenyltransferasen und deren verwendungen |
| GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
| US5972331A (en) | 1995-12-22 | 1999-10-26 | Schering Corporation | Crystalline interferon alpha for pulmonary delivery and method for producing the same |
| CN1213974A (zh) | 1996-01-03 | 1999-04-14 | 葛兰素集团有限公司 | 吸入器具 |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US5980884A (en) | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
| US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| US6087478A (en) | 1998-01-23 | 2000-07-11 | The Rockefeller University | Crystal of the N-terminal domain of a STAT protein and methods of use thereof |
| CN1062565C (zh) | 1998-06-29 | 2001-02-28 | 深圳九先生物工程有限公司 | 重组人α型复合干扰素及其制备方法和用途 |
| US6833256B1 (en) | 1999-06-22 | 2004-12-21 | University Of Maryland | Interferon tau mutants and methods for making them |
| JP3983985B2 (ja) | 2000-03-22 | 2007-09-26 | 株式会社東芝 | ＭｘＡタンパク質の多型遺伝子およびその使用 |
| EP1355939A2 (en) | 2000-11-03 | 2003-10-29 | Pestka Biomedical Laboratories, Inc. | Interferons, uses and compositions related thereto |
| CN1245215C (zh) * | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
| US20060035327A1 (en) * | 2001-02-28 | 2006-02-16 | Guangwen Wei | Recombinant super-compound interferon and uses thereof |
| US8551469B2 (en) * | 2001-02-28 | 2013-10-08 | Superlab Far East Limited | Treatment of tumors and viral diseases with recombinant interferon alpha |
| FR2823764B1 (fr) | 2001-04-24 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides du gene ifn alpha-17 |
| CN1375502A (zh) | 2001-10-25 | 2002-10-23 | 南京药科大学 | 聚乙二醇修饰重组人干扰素 |
| US8158145B2 (en) | 2002-02-19 | 2012-04-17 | Hisamitsu Pharmaceutical Co., Inc. | Percutaneous absorption type plaster |
| US7537803B2 (en) | 2003-04-08 | 2009-05-26 | New Jersey Institute Of Technology | Polymer coating/encapsulation of nanoparticles using a supercritical antisolvent process |
| US20110142887A1 (en) * | 2009-12-15 | 2011-06-16 | Immunovative Therapies Ltd. | Methods and compositions for liquidation of tumors |
| AU2004269390A1 (en) * | 2003-08-28 | 2005-03-10 | Huiyangtech (Usa), Inc. | Uses of spatial configuration to modulate protein function |
| DK1663110T3 (en) * | 2003-08-28 | 2014-03-24 | Superlab Far East Ltd | APPLICATIONS OF INTERFERONES WITH CHANGED SPACIAL STRUCTURE |
| CN1910195A (zh) * | 2003-08-28 | 2007-02-07 | 辉阳科技美国公司 | 通过空间构象调节蛋白质功能 |
| MY141751A (en) * | 2003-08-28 | 2010-06-30 | Sichuan Biotechnology Res Ct | Recombinant super-compound interferon |
| US7585647B2 (en) * | 2003-08-28 | 2009-09-08 | Guangwen Wei | Nucleic acid encoding recombinant interferon |
| FR2862541B1 (fr) * | 2003-11-21 | 2007-04-20 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee d'interferons et leurs applications therapeutiques |
| WO2005067963A1 (en) | 2003-12-23 | 2005-07-28 | Intermune, Inc. | Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens |
| WO2006088473A2 (en) * | 2004-04-23 | 2006-08-24 | Panduranga Rao Koritala | Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents |
| CN1740197B (zh) | 2004-08-26 | 2010-05-12 | 辉阳科技美国公司 | 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用 |
| TWI380993B (zh) * | 2005-03-09 | 2013-01-01 | 輝陽科技美國公司 | 重組型超化合物干擾素之用途 |
| JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| KR20080026135A (ko) | 2005-06-03 | 2008-03-24 | 암브룩스, 인코포레이티드 | 개선된 인간 인터페론 분자 및 이의 용도 |
| WO2007065303A1 (en) | 2005-12-09 | 2007-06-14 | Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd. | Transdermal patch containing isosorbide dinitrate and bisoprolol |
| AU2007281737B2 (en) | 2006-08-04 | 2013-09-19 | Baxter Healthcare S.A. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
| US8095213B1 (en) | 2007-05-31 | 2012-01-10 | Purdue Pharma L.P. | Transdermal patch |
| ES2336873B1 (es) * | 2007-11-07 | 2011-01-24 | Proyecto De Biomedicina Cima, S.L. | Composicion farmaceutica para el tratamiento de cancer. |
| BRPI1014854A2 (pt) * | 2009-03-30 | 2016-05-03 | Cerulean Pharma Inc | "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados" |
| EP2239580B1 (en) | 2009-04-09 | 2013-03-27 | Lga Biotecnologie Srl | Determination of 5-ASA efficacy in CRC prevention and/or treatment by gene expression analysis |
| CN102101886A (zh) | 2009-12-18 | 2011-06-22 | 四川辉阳生命工程股份有限公司 | 构象改变的重组干扰素晶体、其三维结构及应用 |
| CA2812644A1 (en) | 2010-09-27 | 2012-04-05 | Zestagen, S.A. | Compositions and methods for treating neoplasia |
| ES2699965T3 (es) * | 2011-03-10 | 2019-02-13 | Provectus Pharmatech Inc | Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer |
| US20130184437A9 (en) | 2011-06-08 | 2013-07-18 | Guangwen Wei | Design and use of new recombinant interferons with altered spatial configuration and three-dimensional structure |
| WO2013074492A1 (en) | 2011-11-14 | 2013-05-23 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
| US20130273527A1 (en) | 2012-04-13 | 2013-10-17 | Superlab Far East Limited | Method for inducing cell senescence by recombinant interferon with altered spatial configuration |
| WO2014012147A1 (en) * | 2012-07-20 | 2014-01-23 | Latrobe University | Method of diagnosis and treatment |
| TWI718086B (zh) | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
| TWI670494B (zh) | 2013-11-13 | 2019-09-01 | 英屬維爾京群島商遠東超級實驗室有限公司 | 鑒定對腫瘤具有直接抑制作用的干擾素的方法及其用途 |
-
2014
- 2014-01-06 TW TW103100472A patent/TWI718086B/zh not_active IP Right Cessation
- 2014-01-06 TW TW103100470A patent/TW201427681A/zh unknown
- 2014-01-06 TW TW108107884A patent/TWI726291B/zh not_active IP Right Cessation
- 2014-01-07 CA CA2897335A patent/CA2897335A1/en not_active Abandoned
- 2014-01-07 CN CN201480003935.3A patent/CN104902917A/zh active Pending
- 2014-01-07 KR KR1020217018383A patent/KR20210077005A/ko not_active Ceased
- 2014-01-07 JP JP2015551117A patent/JP2016508987A/ja active Pending
- 2014-01-07 EP EP21161499.5A patent/EP3895725A3/en active Pending
- 2014-01-07 WO PCT/CN2014/000019 patent/WO2014106459A2/en not_active Ceased
- 2014-01-07 AU AU2014204386A patent/AU2014204386B2/en active Active
- 2014-01-07 HK HK16102577.9A patent/HK1214528A1/zh unknown
- 2014-01-07 AU AU2014204368A patent/AU2014204368B2/en active Active
- 2014-01-07 WO PCT/CN2014/070212 patent/WO2014106492A2/en not_active Ceased
- 2014-01-07 JP JP2015551113A patent/JP2016506413A/ja active Pending
- 2014-01-07 CA CA2897312A patent/CA2897312C/en active Active
- 2014-01-07 CN CN201480003898.6A patent/CN104994866A/zh active Pending
- 2014-01-07 US US14/759,483 patent/US20150352188A1/en not_active Abandoned
- 2014-01-07 KR KR1020217016953A patent/KR20210069127A/ko not_active Ceased
- 2014-01-07 KR KR1020157021423A patent/KR20150139824A/ko not_active Ceased
- 2014-01-07 KR KR1020157021350A patent/KR20150103284A/ko not_active Ceased
- 2014-01-07 HK HK16104396.4A patent/HK1216394A1/zh unknown
- 2014-01-07 EP EP14735273.6A patent/EP2941266B1/en active Active
- 2014-01-07 EP EP14735427.8A patent/EP2941264B1/en active Active
- 2014-01-07 US US14/759,410 patent/US20160022778A1/en not_active Abandoned
-
2018
- 2018-07-18 US US16/038,704 patent/US20180326012A1/en not_active Abandoned
- 2018-07-25 US US16/044,582 patent/US10874716B2/en active Active
-
2019
- 2019-10-17 JP JP2019190263A patent/JP2020023547A/ja active Pending
-
2020
- 2020-04-02 JP JP2020066723A patent/JP2020105223A/ja active Pending
- 2020-12-29 US US17/136,656 patent/US12109250B2/en active Active
-
2021
- 2021-12-09 JP JP2021200049A patent/JP2022031331A/ja active Pending
- 2021-12-13 US US17/548,598 patent/US12636347B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020105223A5 (enExample) | ||
| Schug et al. | Fentanyl formulations in the management of pain: an update | |
| Yang et al. | Rapidly separable bubble microneedle patch for effective local anesthesia | |
| Anselmo et al. | An overview of clinical and commercial impact of drug delivery systems | |
| Mohammadi et al. | Bacterial cellulose-based composites as vehicles for dermal and transdermal drug delivery: a review | |
| JP6404242B2 (ja) | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 | |
| Wang et al. | Microneedle-mediated treatment for superficial tumors by combining multiple strategies | |
| EP2941264B1 (en) | Recombinant interferon with changed spatial configuration for use in the treatment of malignant pleural effusion, malignant ascites, and/or malignant pericardial effusion | |
| EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
| HK1201475A1 (en) | Methods and compositions for treating pain | |
| JP2012067116A5 (enExample) | ||
| WO2016210376A3 (en) | Therapeutic peptides and methods of use thereof | |
| Volkov et al. | Dexmedetomidine as a part of analgesic component of general anesthesia for laparoscopic operations | |
| Nasim et al. | Novel paradigm of therapeutic intervention for skin cancer: challenges and opportunities | |
| Gandhimathi et al. | Breathable medicine: pulmonary mode of drug delivery | |
| Zhou et al. | A dual PROTAC nanocarrier amplifies DNA damage and STING activation for cancer immunotherapy | |
| KR102494543B1 (ko) | Ｈｐｖ 백신 전달용 용해성 미세바늘 패치 | |
| CN104869986A (zh) | 用于癌症的组合疗法 | |
| CN101623286B (zh) | 包含葫芦素类活性成分的经皮给药组合物 | |
| Gao et al. | Hyperthermic intraperitoneal chemotherapy plus high-frequency diathermic therapy followed by intravenous chemotherapy versus intravenous chemotherapy alone for postoperative adjuvant treatment of gastrointestinal cancer: A comparative research study | |
| WO2024064748A3 (en) | Compositions and methods related to exosomal delivery of therapeutic agents | |
| CA2936070A1 (en) | Poloxamer-based intralesional injections for the delivery of chemotherapeutic agents | |
| Solà et al. | Phase II trial: concurrent radio-chemotherapy with weekly docetaxel for advanced squamous cell carcinoma of head and neck | |
| Gorabi et al. | Microneedles in antiparasitic drug delivery applications | |
| Haonan et al. | ULTRASOUND-TRIGGERED PIEZOCATALYSIS FOR SELECTIVELY CONTROLLED NOCHEMODRUG RELEASE TOGAS ANOENHANCE DRUG PENETRATION IN PANCREATIC CANCER |